Analysis of different HER-2 mutations in breast cancer progression and drug resistance - Wikidata - awgldk - TriplyDB

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

http://www.wikidata.org/entity/Q26797471

about

Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Experimental study on the clinical effects of Xiaoru Sanjie Jiaonang on mammary glands hyperplasia and ki-67.Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer.

P2860

Q36650443-ECE3CE45-E0B2-4982-833C-F33EF3C81228 Q37447938-0E4A2317-C58F-4853-BED0-3DC4F5B3D57E Q37644205-63190637-70CA-408D-9CDD-09FE4F25606E Q48042475-8A463120-D58C-4BB1-A297-582A8641A4D8 Q48205560-F4D8C42C-257C-49FE-AE2E-1CD57163E941 Q52720152-CE281821-71E7-435C-8C5C-B684A32AF864 Q55309854-1416728F-874B-44B5-BDCC-B5099889CF2B

P2860

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

http://www.wikidata.org/entity/Q26797471

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@ast

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@en

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@nl

type

label

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@ast

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@en

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@nl

prefLabel

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@ast

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@en

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@nl

P1433

Q26797471-371602D8-5C31-41F7-B765-E836A6F72566

P1476

Q26797471-855CEF54-BC31-4AFE-AD3E-C5231E948956

P2093

Q26797471-0E82989E-B09B-4088-8611-78A56DD7ABF9

Q26797471-33BAB20B-E727-43AF-9C0B-D4B5CBE36DA5

Q26797471-63A8F93D-98B1-43B7-9452-9B57E7DEA258

Q26797471-8B89E4F9-39A0-4A61-B099-DFCB53C0F1D9

Q26797471-8E45BCC8-5C86-4148-BCFB-1689D990C0E4

Q26797471-9748EF8A-581C-48FC-B2E2-BF73F8195AA7

P275

Q26797471-21676165-7C4C-4518-8090-78F1941506D3

P2860

Q26797471-06EE0841-AF2C-4C93-AB7C-9AF7CF370460

Q26797471-073C5A3E-70B5-4BE5-B338-BD3D6389E1D8

Q26797471-0847AD70-9FDC-4233-B3E7-BDAE47533A57

Q26797471-0981A509-A8A6-4F13-AC18-2F2579033CAA

Q26797471-0AD65CF2-85DD-4194-BDDF-9D3DF09BF519

Q26797471-0C9C31EB-7600-4AFB-BAED-439A3A484B2A

Q26797471-0CFEFA3B-E2A6-42A0-9769-7A05581CEF63

Q26797471-0EAF5512-E4A3-452F-BE51-C93474149480

Q26797471-165E71D2-3BD4-48EE-A87D-FE5E1C5E2C6B

Q26797471-1F1B1AB5-08B7-4A26-AB37-A342AD855B4D

P304

Q26797471-5DFFD2CD-48C3-4497-AD8E-FBFFE2861657

P31

Q26797471-125093EA-7FBC-406E-BC37-BDBEEE9BE1DA

Q26797471-CAAB84C6-AF93-4C79-87BA-5BFA3DC753A1

P356

Q26797471-37C56643-982C-488C-A48E-8551B0EBB834

P407

Q26797471-898661E3-9FD1-4217-8C7E-A29FFB3021D9

P433

Q26797471-47CD6D6D-3B3F-4651-8945-37A55AA19C94

P478

Q26797471-26D3DF0A-0E98-4EC9-9C22-0D57BE07AB2A

P5008

Q26797471-65531C50-1E13-45A5-B47C-32FFE3536523

P577

Q26797471-542A038E-BCCE-42D2-99AA-252A46EDD39A

Q26797471-B6F2116B-4F95-4185-B2FE-F753FA256094

P698

Q26797471-D7446620-3022-43FB-A16C-7D86BC39B021

P921

Q26797471-15250528-C30B-46DF-BE2E-011DA1BD3A8C

Q26797471-27E7BA1B-CAF2-4610-87EB-3064EA78450C

Q26797471-2A85B39C-2C82-468D-B9D2-EE63381EE781

Q26797471-37192E0D-7B3E-422A-B6EC-2D71FB31BC36

Q26797471-4E5C9D83-6D53-4EDE-A786-B617B07BB38F

Q26797471-58F8E59B-E775-466A-A07E-46EC7408DD9B

Q26797471-64761DA0-BDF4-4D19-9F75-BBF7103FC35C

Q26797471-BB9D0065-24A1-4CDC-BBD0-D381282E9980

Q26797471-E573AE42-FFB5-4F51-A339-5041F6A9F17E

Q26797471-F03CEB89-F02C-44EE-9557-BE592454ADD9

P932

Q26797471-40B6E669-E8D6-4383-B57D-912DA2C001B5

P356

P1433

Journal of Cellular and Molecular Medicine

P1476

Analysis of different HER-2 mutations in breast cancer progression and drug resistance

@en

P2093

Lulu Cao

http://www.w3.org/2001/XMLSchema#string

Wenwen Zhang

http://www.w3.org/2001/XMLSchema#string

Xiaoxiang Guan

http://www.w3.org/2001/XMLSchema#string

Yan Shen

http://www.w3.org/2001/XMLSchema#string

Yaqin Shi

http://www.w3.org/2001/XMLSchema#string

Zijia Sun

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Cell signaling by receptor tyrosine kinases

Somatic mutations affect key pathways in lung adenocarcinoma

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

Activating HER2 mutations in HER2 gene amplification negative breast cancer

P304

2691-701

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCMM.12662

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26305917

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

genetic variation

membrane proteins

breast neoplasm

proto-oncogene proteins

tumor biomarkers

physiological phenomena

neoplasm proteins

P932

4687700

http://www.w3.org/2001/XMLSchema#string